Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The Antimuscarinic Clinical Effectiveness Trial (ACET)

Current Medical Research and Opinion

Volumn 18, Issue 4, 2002, Pages 177-184

  Sussman, D ^b   Garely, A ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b NONE

Author keywords

Overactive bladder; Oxybutynin chloride; Tolterodine tartrate; Urge incontinence

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE; BENZHYDRYL DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CRESOL; MANDELIC ACID DERIVATIVE; PHENYLPROPANOLAMINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOCTURIA; PERCEPTION; POLYURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; UNITED STATES; URGE INCONTINENCE; XEROSTOMIA; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; MICTURITION; MIDDLE AGED; NEUROGENIC BLADDER; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; BENZHYDRYL COMPOUNDS; BLADDER, NEUROGENIC; CHOLINERGIC ANTAGONISTS; COMPARATIVE STUDY; CRESOLS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMAN; MALE; MANDELIC ACIDS; MIDDLE AGE; MUSCARINIC ANTAGONISTS; TREATMENT OUTCOME; URINATION; HUMANS; MIDDLE AGED; PHENYLPROPANOLAMINE; URINARY BLADDER, NEUROGENIC;

EID: 0036023507     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000570     Document Type: Article

References (26)

1. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of The International Continence Society
2. Nonpharmacologic treatments for over-active bladder-pelvic floor exercises
3. Behavioral therapy for overactive bladder
4. Muscarinic receptor antagonists in the treatment of overactive bladder
5. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence
6. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of the overactive bladder
7. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder
8. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
9. Validation of the perception of bladder condition measure in overactive bladder
10. From clinical trials to usual practice: Efficacy and effectiveness in clinical pharmacology
11. The science of health technology assessment - Clinical effectiveness of therapeutic interventions
12. Randomized, double blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: Oxybutynin versus propantheline versus placebo
13. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis
14. Tolterodine - A new bladder-selective antimuscarinic agent
15. Clinical experiences with tolterodine
16. A medium term analysis of the subjective efficacy of treatment for women with destrusor instability and low bladder compliance
17. Twelve-month treatment of overactive bladder: Efficacy and tolerability of tolterodine
18. Long-term (12-months) efficacy and tolerability of tolterodine once daily in the treatment of overactive bladder. ICS 2001
19. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence
20. One-year prospective, open-label trial of controlled-release oxybutynin for overactive bladder in a community-based population
21. Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT study
22. Medical treatment of overactive bladder
23. Evaluation of female lower urinary tract symptoms: Overview and update
24. Non-invasive outcome measures of urinary incontinence and lower urinary tract symptoms: A multicenter study of micturition diaries and pad tests
25. Tolterodine once daily: Selectivity for the bladder over effects on salivation compared to Ditropan XL